This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine.